Legal Information
MILLIPLEX is a registered trademark of Merck KGaA, Darmstadt, Germany
Luminex is a registered trademark of Luminex Corp
xMAP is a registered trademark of Luminex Corp
Application
MILLIPLEX® Qualified assays undergo rigorous assay development, verification, and Quality Control testing to achieve optimal performance. Simultaneously analyze up to 6 analytes in human cerebrospinal fluid (CSF).Analytes included: α-Synuclein, DJ1/PARK7, Glial fibrillary acidic protein (GFAP), Neuron specific enolase (NSE), Transglutaminase 2 (TGM2), Ubiquitin carboxyl-terminal esterase L1 (UCHL1/PARK5).Assay Characteristics: Refer to kit protocol for assay cross-reactivity, sensitivity, precision, and accuracy.
Disclaimer
For research use only. Not for use in diagnostic procedures.Label License/Sticker for Assay Product:By opening the packaging containing this Assay Product (which contains fluorescently labeled microsphere beads authorized by Luminex Corporation) or using this Assay Product in any manner, you are consenting and agreeing to be bound by the End User Terms and Conditions and the End User License Agreement available at http://support.diasorin.com/end-user-terms-and-conditions/. If you do not agree to all of the terms and conditions, you must promptly return this Assay Product for a full refund prior to using it in any manner.
Features and Benefits
Comprehensive Neurological Assessment: Simultaneously quantify six critical biomarkers spanning neuronal damage, glial activation, and protein aggregation pathways, providing complete neurological dysfunction profiling in cerebrospinal fluid samples.Parkinson′s Disease Research Focus: Leverage specialized biomarkers including α-synuclein and DJ1/PARK7 that are directly implicated in Parkinson′s pathology, enabling targeted research into movement disorders and synucleinopathies.CSF-Optimized Performance: Specifically designed and verified for cerebrospinal fluid analysis, ensuring accurate quantification of brain-derived biomarkers in this challenging but clinically relevant sample matrix.Cross-Condition Biomarker Power: Utilize markers relevant to traumatic brain injury, neurodegenerative diseases, and neuroinflammation, maximizing research versatility across diverse neurological conditions and study designs.Configurable Panel Flexibility: Design your ideal research solution by selecting any combination of the 6 analytes, creating tailored assays that perfectly align with your specific neurological research objectives.
General description
Cellular stress and structural damage in the brain are reflected in specific protein signatures. GFAP signals astrocyte activation and blood-brain barrier disruption. UCHL1, a neuron-specific enzyme, increases after traumatic brain injury. α-Synuclein, central to Parkinson′s pathology, affects synaptic function and aggregates into Lewy bodies. DJ1 (PARK7) mitigates oxidative stress, while NSE and TGM2 track neuronal integrity and cellular resilience.
